INVENTIVA SA (6IV.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:6IV - FR0013233012 - Common Stock
6IV.DE Key Statistics, Chart & Performance
The current stock price of 6IV.DE is 3.41 EUR.
6IV.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.78 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.02M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 699.13M | ||
| ALCLS.PA | CELLECTIS | N/A | 444.94M |
Related stock screener links
About 6IV.DE
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA
50 rue de Dijon, Daix
Daix OCCITANIE FR
Employees: 116
Phone: 33380447500
INVENTIVA SA / 6IV.DE FAQ
What does 6IV do?
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
What is the current price of 6IV stock?
The current stock price of 6IV.DE is 3.41 EUR.
Does 6IV stock pay dividends?
6IV.DE does not pay a dividend.
What is the ChartMill rating of INVENTIVA SA stock?
6IV.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is 6IV.DE stock listed?
6IV.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the Price/Earnings (PE) ratio of INVENTIVA SA (6IV.DE)?
INVENTIVA SA (6IV.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.62).
Can you provide the number of employees for INVENTIVA SA?
INVENTIVA SA (6IV.DE) currently has 116 employees.
6IV.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 6IV.DE.
6IV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to 6IV.DE. 6IV.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
6IV.DE Financial Highlights
Over the last trailing twelve months 6IV.DE reported a non-GAAP Earnings per Share(EPS) of -3.62. The EPS decreased by -74.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.84% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
6IV.DE Forecast & Estimates
For the next year, analysts expect an EPS growth of 38.93% and a revenue growth -14.87% for 6IV.DE